Physician profile
Adarsh V Mudgil
NPI 1205961927
$2,093.41
in general payments reported to CMS, 2019-2025
19 companies · $785 in 2025
The $785 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $226 · 2021: $66.81 · 2022: $44.00 · 2023: $140 · 2024: $685 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $85.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.28 |
| Education | $85.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $467.59 | 2020-2025 | |
| Janssen Biotech, INC. | $254.35 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $239.71 | 2019-2020 | |
| Incyte Corporation | $202.62 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $188.24 | 2024-2025 | |
| Lilly USA, LLC | $102.38 | 2023-2025 | Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $85.97 | 2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $85.47 | 2024 | Dupixent |
| Leo Pharma INC. | $80.14 | 2020-2022 | |
| Pfizer INC. | $66.67 | 2024 | |
| Abbvie INC. | $54.72 | 2020-2025 | |
| Genzyme Corporation | $47.73 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $46.07 | 2021-2023 | |
| Krystal Biotech INC | $35.55 | 2025 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.48 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $35.13 | 2024 | Vtama |
| Allergan, INC. | $32.73 | 2019 | |
| Amgen INC. | $17.29 | 2025 | Otezla |
| Botanix Sb INC | $15.57 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adarsh Mudgil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.